Middle East & Africa Human Microbiome Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The human microbiome market in the Middle East and Africa is projected to grow significantly, reaching an estimated US$ 48.22 million by 2031, up from US$ 182.83 million in 2023, with a compound annual growth rate (CAGR) of 18.1% from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: Saudi Arabia, the UAE, South Africa, and the broader Middle East and Africa. The region is witnessing a rise in chronic diseases, including diabetes, skin disorders, Crohn's disease, and cystic fibrosis. Additionally, the increasing prevalence of unhealthy lifestyles is expected to boost the demand for human microbiome products and services. Research and development initiatives by both governments and private companies are anticipated to further stimulate market growth in the coming years.

Market Segmentation

The human microbiome market in the Middle East and Africa is categorized by type, application, and disease type:

Type: The market is split into products and software/services, with the product segment dominating in 2023. This segment includes probiotics and prebiotics.
Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT disorders leading the market in 2023.

Market Outlook

Government initiatives play a crucial role in the growth of the human microbiome market. Substantial funding and grants for microbiome research are provided by governments, which accelerates the development of new treatments, devices, and diagnostics. For example, the National Institutes of Health (NIH) has launched the Human Microbiome Project, allocating US$ 115 million over five years to enhance understanding of human health and improve disease prevention, diagnosis, and treatment.

Regulatory frameworks for microbiome-based products are also evolving, which can reduce the time and costs associated with bringing new treatments to market. Well-defined regulations ensure product safety and efficacy, fostering consumer trust and market acceptance.

The field of microbiome-based therapeutics is rapidly expanding, particularly following the recent approval of Vowst by Seres Therapeutics for treating C. difficile infections, which has heightened interest in microbiome therapies.

Country Insights

The human microbiome market in the Middle East and Africa includes South Africa, Saudi Arabia, the UAE, and the Rest of the region, with South Africa holding the largest market share in 2023. The increase in research studies in South Africa is driving market growth. For instance, a study published in PubMed Central in August 2021 highlighted the relationship between clinical and environmental factors and gut microbiota profiles in young South African children, indicating a protective effect of certain microbiota against atopic dermatitis.

The rising incidence of diabetes is also contributing to market growth in South Africa. Dysbiosis, or an imbalance in gut microbiota, is recognized as a potential risk factor for insulin resistance in Type 2 diabetes patients. According to the IDF Diabetes Atlas, approximately 4 million adults in South Africa had diabetes in 2021, with projections suggesting this number could rise to nearly 7 million by 2045. The development of microbiome therapeutics aimed at treating diabetes is further propelling the human microbiome market in the country.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are pursuing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa human microbiome market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa human microbiome market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution. Show more